For most adults without existing heart disease, large randomized trials have found that standard omega-3 supplements do not meaningfully reduce cardiovascular events: the 2018 VITAL trial of more than 25,000 US adults found a 1-gram daily omega-3 supplement did not significantly reduce major cardiovascular events compared with placebo over about five years, and the 2019 meta-analysis in JAMA Cardiology that pooled 10 trials and over 77,000 participants concluded that omega-3 supplementation was not associated with lower risk of fatal or nonfatal coronary heart disease or major vascular events. One prescription formulation at prescription doses has shown a benefit, but in a trial with complications that researchers continue to debate.
Newspaper Daily publishes information, not medical advice. Decisions about fish oil, prescription omega-3 drugs, or major dietary changes belong with a physician, particularly for people with heart disease, high triglycerides, atrial fibrillation, or bleeding risk.
Why did researchers expect omega-3 to help the heart?
The hypothesis grew from three observation types. First, cohort studies in the 1970s noted low cardiovascular mortality among Greenland Inuit populations eating marine diets. Second, randomized trials in the late 1980s and 1990s — most famously the 1999 GISSI-Prevenzione trial in more than 11,000 Italian heart attack survivors — found that omega-3 supplementation was associated with fewer cardiac deaths. Third, mechanistic work showed EPA and DHA lower triglycerides and modestly reduce inflammation. The omega-3 index, a blood measure of EPA and DHA in red cell membranes, was associated in cohorts with lower cardiac mortality.
None of that anticipated what happened when the supplement met the modern large, placebo-controlled trial.
What did the biggest modern trials find?
Three landmark randomized trials, all funded in part by public money, tested standard doses against placebo:
- VITAL (2018): 25,871 US adults, 1 gram per day of fish oil for about 5.3 years, found no significant reduction in major cardiovascular events overall; a secondary signal for heart attack — about a 28 percent lower risk — was flagged as exploratory and required confirmation
- ASCEND (2018): 15,480 UK adults with diabetes, 1 gram per day for about 7.4 years, found no significant difference in serious vascular events
- GISSI-HF and ORIGIN (2012): trials in heart failure and prediabetes populations, both finding no significant reduction in cardiovascular death or events at 1-gram doses
The 2019 JAMA Cardiology meta-analysis drew the bottom line across such studies: no significant association between omega-3 supplementation and reduced coronary or major vascular events when trials of standard doses were pooled.
What about the REDUCE-IT trial and icosapent ethyl?
REDUCE-IT, published in the New England Journal of Medicine in 2019, was the outlier. It enrolled 8,179 adults with elevated triglycerides who were already on statins and randomized them to 4 grams per day of icosapent ethyl — a purified EPA-only prescription drug, not a dietary supplement — or placebo. The trial found a 25 percent relative reduction in the composite cardiovascular endpoint. The FDA added a cardiovascular-indication label to the drug in 2019.
The caveat that shaped subsequent debate: the placebo arm used mineral oil, which some investigators argued might itself have raised cardiovascular risk by interfering with statin absorption, inflating the apparent benefit. A 2020 trial of a different omega-3 product, STRENGTH, used a corn-oil placebo and found no benefit — a result many researchers read as weakening the mineral-oil explanation but also failing to confirm REDUCE-IT. Professional societies have kept icosapent ethyl as an option for a narrow high-risk population while stopping short of blanket endorsement.
Related stories: Intermittent Fasting: What the Evidence Shows So Far · Ultra-Processed Foods: What the Research Says About Health Risks.
Do omega-3 supplements raise any risks?
Two have drawn recent attention. A 2021 analysis in the journal Circulation using UK Biobank data found that regular fish oil supplement use was associated with a modestly higher risk of atrial fibrillation at higher doses, and the 2024 STRENGTH and REDUCE-IT safety pools plus a 2024 European Heart Journal – Cardiovascular Pharmacotherapy meta-analysis reported an AF signal of roughly 25 percent increased risk with omega-3 supplementation — mainly at prescription doses. Bleeding risk, an older concern, has generally not materialized at supplement doses in modern trials, though guidance for people on anticoagulants still calls for clinician input. The FDA considers intakes up to 3 grams per day of combined EPA and DHA generally safe for healthy adults, with supplement labels historically capped at 1 gram per serving absent notified safety data.
Is eating fish better than taking capsules?
The evidence base says yes, for the general population. Cohort analyses within VITAL and older studies such as the Nurses' Health Study found fish intake itself associated with lower cardiovascular mortality, an association that persisted even among supplement users — suggesting compounds and dietary patterns beyond the two fatty acids matter. The Dietary Guidelines for Americans advise at least two seafood meals weekly, and the American Heart Association's 2018 science advisory recommends one to two seafood meals per week for cardiovascular health while concluding that supplementation for the general public is not supported. For people who do not eat fish, the AHA noted supplement decisions should be individualized with a clinician.
Do omega-3s help anything else?
Effects on triglycerides are real: prescription omega-3 products are FDA-approved for very high triglycerides at gram-scale doses, and meta-analyses consistently show dose-dependent triglyceride lowering. For other claims the record thins. A 2022 JAMA trial of high-dose omega-3 after heart transplant found no benefit and raised infection concerns; depression trials remain mixed, with the American Psychiatric Association noting insufficient evidence for routine use; and cognitive outcomes in the 2015 Alzheimer's-focused trials were largely null, though a small body of research suggests possible modest benefits in early-stage disease.
What should supplement users know about products?
Dietary supplements are regulated differently from drugs: under the Dietary Supplement Health and Education Act, manufacturers market products without FDA pre-approval of efficacy claims, and third-party testing programs such as USP or NSF verify contents rather than benefits. Analyses of commercial fish oil have found oxidation and content variability, and the products' long-term storage degrades potency. Oxidized formulations are a standing research question, with a 2023 review noting that rancidity markers vary widely across commercial products.
When to see a doctor or registered dietitian
Clinician input matters when triglycerides are very high, where prescription options and cause-finding are appropriate; when atrial fibrillation has been diagnosed, given the dose-related risk signal; when anticoagulants or antiplatelet drugs are taken, because combined bleeding effects need individual assessment; before surgery, when supplement use should be disclosed; and when planning pregnancy, where DHA guidance differs from general adult advice. Anyone experiencing chest symptoms should seek urgent care rather than adjusting supplements.
The bottom line on omega-3 and the heart
The story the large trials tell is narrower than the supplement aisle suggests: standard fish oil capsules, tested against placebo in more than 77,000 participants across pooled randomized evidence, have not significantly reduced major cardiovascular events, and a safety signal for atrial fibrillation at high doses has emerged. The purified prescription EPA drug icosapent ethyl reduced events in one contested but labeled trial for a specific high-risk group. Fish as food retains the strongest general-population support, per the American Heart Association's advisory — a conclusion that has held through 2026.